May 17, 2020

Hospira re-launches oxaliplatin injection in U.S.

re-launched oxaliplatin injection
generic version of Sanofi
2 min
Hospira re-launches oxaliplatin injection
Hospira Inc said it has re-launched oxaliplatin injection in the U.S. The worlds leading provider of injectible drugs and infusion technologies has lau...

Hospira Inc said it has re-launched oxaliplatin injection in the U.S. The world’s leading provider of injectible drugs and infusion technologies has launched the injection, its generic version of Sanofi’s chemotherapy medication Eloxatin®. The sale of Eloxatin last year in the U.S. was approximately $1.5 billion.  

Joshua Gordon, Vice President, Specialty Pharmaceuticals, said, “We are excited to once again be able to provide this critical oncology drug to our patients and customers.” “Hospira is committed to bringing safe,  lower-cost generic versions of important medications to the market as soon as possible, and in this case we’re able to do so a year ahead of patent expiration for the originator product, which will contribute to much-needed cost savings for our customers," he added.

The oxaliplatin injection is a widely used oncology agent used to help treat colon and colorectal cancer. The company will initially offer the injection in 50 mg and 100 mg single-use vials.  It is a solution form of the product.

This injection was initially launched in August 2009 following a favorable ruling patent litigation with Sanofi.The company settled litigation with Sanofi in 2010 under the agreement which called for the eventual suspension of the sales of Hospira at the end of June 2010, with the right to re-launch the product in advance of the patent expiry, the news reports said.

Hospira Inc is a global market leader for the generic injectable pharmaceuticals. It is uniquely positioned to Advance Wellness by improving patent and caregiver safety while reducing the cost of healthcare.

Share article

Jun 21, 2021

Dubai's new smart neuro spinal hospital: need to know

2 min
The brand new Neuro Spinal Hospital and Radiosurgery Centre has opened in Dubai. We take a look at what this smart hospital offers. 

We take a look at Dubai's new smart hospital. 

What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah.   It is also the UAE’s first hospital to have surgical robots. 

Where: The hospital is located in the Dubai Science Park. Founded in 2005,  Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day. 

Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital. 

Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.  

Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our  next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.

"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”

Share article